Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Crisis resolution Clear all
Recruiting Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

NCT06699849
View directory record Official record
Conditions
Sickle Cell Disease Vaso-occlusive Crisis
Interventions
CSL889, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Oakland, California • Orange, California • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

NCT02411708
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
SANGUINATE, Placebo
Drug
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Hollywood, Florida • Tampa, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 10, 2026, 8:14 AM EDT
Recruiting Phase 4 Interventional

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

NCT04657822
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 100 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Augusta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Completed Phase 4 Interventional

Low Dose Ketamine and Acute Pain Crisis

NCT04330183
View directory record Official record
Conditions
Sickle Cell Crisis
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Sep 10, 2026, 8:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Suicide Intervention Strategies for Teens During High Risk Periods

NCT05078970
View directory record Official record
Conditions
Suicide Attempts, Suicidal Ideation, Suicide and Self-harm, Suicide Threat
Interventions
Safety Planning Intervention+ (SPI+), Collaborative Assessment and Management of Suicidality (CAMS), Treatment As Usual
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 17 Years
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Columbus, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 10, 2026, 8:14 AM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Gammaglobulin for Sickle Cell Pain Crises

NCT01757418
View directory record Official record
Conditions
Sickle Cell Disease, Pain
Interventions
Immune Globulin Intravenous (IVIG), Normal saline
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
6 Years to 13 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 10, 2026, 8:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Navigation and Parent Peer Support to Promote Access

NCT04029220
View directory record Official record
Conditions
Mental Disorder, Child, Mental Health, Family Health
Interventions
Parent Peer Navigation
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 99 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Salem, Oregon • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Sep 10, 2026, 8:14 AM EDT
Terminated Not applicable Interventional

Reducing Suicide Risk in Older Veterans Using Problem Solving Therapy

NCT04763330
View directory record Official record
Conditions
Suicidal Ideation, Depressive Disorder, Anxiety Disorders, Post Traumatic Stress Disorder
Interventions
Enhanced Usual Care (EUC), Problem Solving Therapy (PST) plus EUC
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Palo Alto, California • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Feasibility of Mobile and Technology Assisted Aftercare Services for Crisis Stabilization Units

NCT04899934
View directory record Official record
Conditions
Substance Abuse, Criminal Behavior, Mental Disorder
Interventions
mobile and technology assisted aftercare, Treatment as usual
Behavioral · Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 10, 2026, 8:14 AM EDT
Not yet recruiting Not applicable Interventional

Rapid Personalization of Safety Plans for Psychiatrically Hospitalized Veterans at High-Risk for Suicide

NCT07507786
View directory record Official record
Conditions
Suicide
Interventions
Personalized Safety Plans, Safety Plans as Usual + Calls
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Not listed Phase 1 Interventional

Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder

NCT00269139
View directory record Official record
Conditions
Borderline Personality Disorder, Post-Traumatic Stress Disorders
Interventions
Crisis resolution
Behavioral
Lead sponsor
Laddis, Andreas, M.D.
Individual
Eligibility
19 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pocasset, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2006 · Synced Sep 10, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 10, 2026, 8:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

NCT03814746
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizumab (SEG101), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?

NCT03541980
View directory record Official record
Conditions
Sickle Cell Anemia Crisis
Interventions
Acetaminophen, Normal saline
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
4 Years to 16 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Newark, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 10, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

NCT01522196
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Varespladib, Placebo (Normal Saline)
Drug · Other
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
5 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 10, 2026, 8:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

NCT00834899
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 10, 2026, 8:14 AM EDT
Completed Phase 4 Interventional Results available

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

NCT01482091
View directory record Official record
Conditions
Anemia, Sickle Cell, Pain
Interventions
Fentanyl Citrate, Normal Saline
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
3 Years to 21 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Sep 10, 2026, 8:14 AM EDT
Recruiting Not applicable Interventional

Removing Barriers: Community Partnering for Innovative Solutions to the Opioid Crisis

NCT05665179
View directory record Official record
Conditions
Opioid Use Disorder, Alcohol Use Disorder, Health Risk Behaviors, Criminal Behavior, Housing Problems, Overdose of Opiate
Interventions
Removing Barriers to Recovery
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 10, 2026, 8:14 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 10, 2026, 8:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT06439082
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crizanlizumab, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

NCT03474965
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 10, 2026, 8:14 AM EDT